Jindal Saw Regulatory Approval

Jindal Saw Earnings Call Transcript: Key Takeaways

Revenue growth is masked by severe EBITDA compression due to geopolitical delays in the MENA region and rising raw material costs.

Jindal Saw Debt & Borrowing

Jindal Saw Ltd. submitted its Security Cover Certificate for the quarter ended September 30, 2026, as per Regulation 54(3) of SEBI listing regulations.

Jindal Saw Other Announcement

Jindal Saw Ltd. filed its quarterly statement confirming the utilization of NCD proceeds as per SEBI regulations. No deviations were reported for the period.

Jindal Saw Investor Presentation: Key Takeaways

Jindal Saw reports Q2 FY27 consolidated revenue of ₹45,231 Million with PAT at ₹353 Million. Performance was severely impacted by MENA regional instability and domestic water pipe headwinds.

Jindal Saw Q2 FY27 Results: Net Profit ₹35.3 Cr, Down 74.5% YoY

Jindal Saw Ltd reported revenue from operations of ₹4,472 Cr (+5.6% YoY) and net profit of ₹35.3 Cr (-74.5% YoY) for Q2 FY27.

Key figure

Net profit ₹35.3 Cr · -74.5% YoY

Jindal Saw Board Meeting Date

Jindal Saw Ltd has scheduled a board meeting for October 16, 2026. The board will consider and approve unaudited financial results for the quarter ended September 30, 2026.

RNFI Services Regulatory Approval

RNFI received RBI no-objection to acquire control of Smart Payment Solutions Private Limited. Remaining tranches may proceed, but no transaction value is disclosed.

Shalby Regulatory Approval

Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.

Elantas Beck India Regulatory Approval

Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.

Kalyani Cast-Tech Regulatory Approval

Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.

Mukka Proteins Regulatory Approval

Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.

Execution

October 1, 2026 to December 31, 2027

Canara Bank Regulatory Approval

Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.

Value

₹1,500 Cr